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Abstract. Neutral proleinases of neutrophilic polymorphonuclear leukocytes were fo llowed up cytochemically in 
blood smears of 12 patients submitted to regular hemodialysis treatment (ROT). Halo formation (ring-shaped area 
around each neutrophil due to protein degradation) was reduced in all patients with end-stage renal disease under 
ROT. Concomitant to the devclopment of leukopenia, a maximal increase of the plasma levels of the granulocytic 
elastase in complcx with a l-proteinase inhibitor was observed 3 h after starting hemodialysis (+409%; p < 0.00 I). On 
the other hand, Ihe proteolytic activity ofthe plasma sampies against azocasein as substrate, being significantly higher 
(+244%; p < 0.00 1) in ROT patients compared with healthy controls, decreased pennanently during therapy (- 7 1 %; 
p < 0.00 I; 3 h after initiation of the treatment). The mechanisms of release as weil as of elimination of proteolytic 
activity due to ROT are discussed. 
Introduction 
Hemodialysis therapy is associated with a consider-
able loss ofamino acids and glucose (I , 2]. On the other 
hand, hepatic gluconeogenesis is enhanced during renal 
insufficiency (3-51. Two possible causes of the reported 
increase in intradialytic protein catabolism [6) would be 
gluconeogenesis to replace glucose loss (during glucose-
free dialysis) and protein breakdown to replace amino 
acid loss [7J. Glucose was fo und to be inefTective in 
reducing dialysis-induced catabolism. The average intra-
dialytic urea generation was increased by 28% with glu-
cose-free dialysis compared with 24 and 25%, respective-
Iy, in the presence of glucose in the dialysate at a level of 
II or 26 mmol/I [7). Furthermore, the replacement ofthe 
loss of am ino acids during dialysis by continuous amino 
acid infusion did not lower intradialytic protein catabo-
lism, but appeared to increase it [6]. 
Several studies have shown that proteinases partici-
pate in the protein catabolism ofpatients with hypercata-
bolic acute renal failure [8-1 1). Therefore, we evaluated 
the possibility ofenhanced protein breakdown by proteo-
lytic enzymes liberated or activated during hemodialysis 
therapy. The rational for this is given by the high concen-
tration of proteinases in neutrophil granulocytes and the 
well-known decrease of white blood cells followed by 
increased enzyme liberation after initiation of hemodia-
lysis therapy - for review, see Heidland et al. (1 2). The 
aim of our present slUdy was twofold: (I) the cytochemi-
cal evaluation ofneutral proteinases ofneutrophilic poly-
morphonuclear (PMN) leukocytes of patients subjected 
to regular hemodialysis treatment (ROT), and (2) the 
detection of an increased liberation of the granulocytic 
proteinase elastase by measurement of the elastase-al-
proteinase inhibitor (E-aIPI) complex in plasma sampies 
of ROT patients. The plasma level of this complex was 
shown to be a suitable indicator of elastase liberation 
from activated or desintegrated granulocytes. 
Material and Methods 
We repon here the resuhs obtained in 12 chronically uremic 
patients(9 men), age<l47.3 ± 4.0 years (mean ± SEM , range 22-66), 
undergoing ROT for 4 1.3 ± 11.6 months (range 4-124). Hemodia· 
lysis was performed three limes per weck for 5 h with Gambro Lun· 
dia Optima and a glucose-frec bath containing acetate. 4 patients 
suffered from diabet ic glomerulosclerosis, 2 from po1ycystic kidney 
degeneration and 6 from chronic glomerulonephrit is. Blood cells 
were counted by an electronic counter (Coulter·Counter-Model B). 
Fun her blood constituents were determined as folIows: creatinine 
11.5 ± 0.8 mgldl (range 7.2-16.9); urea nitrogen 76.9 ± 4.7 mgldl 
(range 54-105); hemoglobin 9.2 ± 0.5 gldl (range 7.4-13.2), and 
214 
filt. l . 8100d smear from a healthy subjccl. Fixat ion was per-
forme<! using formaline sublimate. Thc smear was incubated with 
0.25 M NaQ borate buffer (pH 8.5) for 120 min 31 37 · Cand stained 
with col1oidal ira n. 
hcmatocri t 30.3 ± 1.7% (range 23.7-42.5). Plasma sampies were 
oblained by withdrawing 4.5 ml ofvenous blood in ta plastic syringes 
oontaining 0.5 ml of sodium ci trate (2.2g/100ml disti1led water) . 
Plasma was scparaled from blood within 30 min after sampIe callee-
lion 10 prevent leakage of Icukocylc constituents. Thc plasma speci-
mcns were Store<! at - 70·C until aSS3yed. 
Thc inhibilOry activi ty of anli lhrombin 111 (AT 111) againSI 
thrombin was detcrmined using the Ihrombin-specific chromogenie 
substrate S·2238 (Deutsche Kahi. Munich. FRG). Thc inhibilory 
activit)' of the al-proteinase inhibi tor (aI PI = a l-antitrypsin) was 
measured with a commercial test system (Boehringer. Mannheim, 
FRG). Plasma conccnlrations of o, j-macroglobulin (alM). a lP!. albu-
min as welt as com plcmenlcomponents Cl and C. were eval uated by 
a radial immunodiffusion technique with standardized immunodif-
fusion platcs (lkhringwerke AG. Marburg. FRG). 
Quantitati ve estimation of the plasma levels of the E-aI PI com-
plex was canied out with a highly sensitive enzyme-linked immu-
noassay [13]. Protcolytic activi ty of the plasma sampIes was mea-
sured using azocasein as substrate as previously described [9. 14]. 
Proteinase activity o fthe neulrophilic PMN leukoc:yles was observed 
with the cytochemicaltest of KleJst'fI [15]. 
Results were expresscd as mean values :t SEM. Statistical evalu· 
ation was performed by Ihe Student's ttest. 
Results 
The cytochemicaltest of KIessen (15J was used to eval-
uate thc activity of neutrophilic PM N leukocyte pro-
teases. These enzymes are released from the PM N neu-
trophi ls of healthy subjects in blood smears fo llowing 
incubation wi th sodium chloride borate buffer. Proteo-
lytic act ivity is revealed by a ring-shaped area around 
each neutrophil (fi g. 1). Thi s halo effect is due to erythro-
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"' i". 2. Absence of halo formation in a blood smear of a ROT 
patient 30 min after initiation of hcmodialysis therapy. For incuba-
tion conditions see legend 10 figure I. 
cyte hemolysis and plasma protein degradation. Halo for-
mat ion was reduced in thc blood smears of all patients 
with end-stage renal d isease undergoing RDT (fi g. 2). 
The effect of hemodialysis on leukocytes, plasma lev-
els ofthe E-a IPI complex as weil as on (t IPI activilY and 
concentration is shown in table I. Therc was a decrcase of 
wh itc blood cells 10 min (2 l.l %; n.s.) and 30 min 
(41.1 %; p < 0 .(0 1) after in itiation of hemodialysis ther-
apy. We observed maximum levels ofthe plasma E-(tI PI 
complex after 3 h (+409%; p < 0.00 I). However, plasma 
(tI PI activity and concentrat ion were unchanged d uring 
hemodialysis therapy. 
The plasma levels of a 2M (before dialysi5, 244 ± 17; 
after 3 h of dialysis therapy, 257 ± 31 mgld l), AT 111 
(91. 3 ± 2.5 vs. 95.2 ± 4.3%), complement componcn ts 
Cd l 54 ± 6V5. 160 ± 8mgldl)orCd61.7 ± 3.8vs. 
64.6 ± 3.7 mgld l) remained also unchanged . Dialysis 
therapy was performed to maintain a constant body 
weight d uring the fi rst 3 h. Plasma albumin concentration 
(3.77 ± 1. 12 vs. 3.88 ± 0. 14 g1dl) or hematocrit (30.3 ± 
1.7 vs. 3 1.3 ± 2.0%) wcre in thc sa me range be fore and 
3 h afte r start ing hemodialysis Ihcrapy. 
Using azocasein as a substrate, the proteolytic activity 
ofthc plasma sam pies was significan tly higher (+ 244 %; p 
< 0.01) beforc dialysis therapy compared with plasma 
sam pies of healthy cont rols (0.052 ± 0.004 U/ mg pro-
tein). During dialysis therapy. however, there was aper-
manent decrease ofthis plasma proteinase acti vity (0. 127 
± 0.0 19 vs. 0.037 ± 0.007 U/mg; -7 1%; p < 0.00 1; 
table I). 
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Table I. Effect ofhemodialysis therapy on Icukocyte counts, plasma E-u IPI complex, proteinase activity as well as on activity and plasma 
conccntration of a lPI . 
Time. min 
0 10 30 60 120 180 
Leukocytes. cells/mm) 7,133:t582 5.625 :t 696 4,200:t25 1< 6,658 :t 441 5.950:t607 7,192:t824 
E-a IPI. nglml 188:t20 196±25 326:t 56" 373:t J2c 602 :t 84< 769 ± 128< 
Proteinase activity. U/mg protein 0. 127:t0.0 19 0.103±0.014 0.095 :t 0.014 0.087:t0.013 0.059 ± 0.010b 0.037 ± 0.007< 
a lPI . Ulml 1.98:t0.l l 1.89±0. 1I 2.07:t0. 10 2.06±0.09 2.01 :t 0.09 2.08±0.11 
a lPI. mgldl 254 :t 14 257 ± 13 268:t 13 258 :t 12 260 ± 11 271 :t 13 
Mean values :!: SEM from 12 experiments beforc and dunng hemodialysis therapy. 
" p < 0.05: b p < O.DI: · p < 0.00 1. 
Diseussion 
It has been shown recently that glucose in the dialysate 
(7] as weil as continuous amino acid infusion [6J are inef-
feclive in preventing thc p3thological calabolic cvents 
observed during hemodialysis. The pathogenesis of he-
modia lysis-induced protein catabolism remains so far 
undear. One pathogenetic factor could bc Ihe release o f 
granulocyte proteinases after starting hemodialysis thera-
py. Craddock et al. [16] ha ve de monstratcd hemodialysis-
induced leukopenia and pulmonary vascular leukoSlasis 
resulting from complement activation by dialyzer cello-
phane membranes. 
Neutrophil granulocytes contain a broad variety of 
agents that are involved in the defence and digestion of 
in vading microorganisms [1 7J. These include clastase 
[1 7, 18J, cathepsin G , cathepsi n B, cathepsin 0 and col-
lagenasc [1 9-24). Lysosomal proteinases are not exclu-
sively restricted 10 their intracellular compartment, the 
lysosomes. They may be released in tra- as weil as extra-
cell ularly during phagocytosis, exposure to antigen-anti-
body complexes, complement components and toxic sub-
stances such as endotoxi ns or during cell death [25 , 26). 
Especially under pathological conditions massive release 
ofproteases and other lysosomal factors may occur. They 
might cause tissue injury [27 , 28J and consumption of 
plasma proteins by unspeci fic proteolytic degradation as 
soon as the levels ofthe controlling proteinase inhibitors 
in plasma and tissues are insufficient [29]. 
Granulocyte elastase is the most potent candidate for 
unspecific degradation because of its broad substrate 
specificity and the large amount present in the PM N 
granulocytes - for review, see Heidland et al. (1 2]. It 
degrades various plasma proteins such as transfemn [Jo-
chum and Lander. unpublishcd data], immunoglobulins 
[30, 3 1] and fibronectin [32]. In vitra elastase rapidly 
inacti vates fibrinogen [33, 34] and several other clotting 
factors (35, 36]. h also causes a limited degradation o fthe 
third and fifth factor ofhuman complement [3 7, 38]. 
Granulocyte elastase could be released during hemo-
dia lysis due to the contact of blood cells wüh the blood 
Hnes and the dialyzer membrane (euprophane). Such con-
taet may result in a so-ealled ' frustrated phagocytosis' 
known to be associatcd with an extracellular release of 
Iysosomal proteinases. The redueed proteolytic acti vity 
of PMN leukocytes in blood smears obtained 30 min 
after onse! ofhemodialysis and the eoncomitant inerease 
of E-U1PI plasma levels may be regarded as possible indi-
calors of this 'escape' reaction. On the other hand, pro-
teinase release due 10 cell death must be also taken into 
account. Since, however, leukopenia docs not strictly par-
allel the inerease of the E-UIPI levels during hemo-
dialysis, pulmonary vascular leukostasis resulting from 
com plement activation by dialyzer cellophane mem-
branes may be an additional source of local lysosomal 
enzyme release (1 6J. This event could indeed be respon-
sible for the delayed release of elastase into the circula-
tion. Although plasma activity and concentrat ion OfU1Pl. 
the dominating elastase inhibitor [39], were unchanged 
during hemodialysis therapy (table I), the liberation of 
granulocytic elastase together with other Iysosomal en-
zymes, primarily wühin the lung, might lead to a repeated 
local proteinase-proteinase inhibitor imbalance (40-42) 
thus favoring pulmonary disease in long-tenn ROT pa-
tients. 
The deleterious release of granulocytic proteinases 
during hemodialysis is partly counteracted by the dimi-
nution of'unspecific' proteolytic (azocasei n-hydrolyzing) 
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activity accumulated in plasma in thc dialysis-free inter-
val . Thc decrease of Ihis unspecific proteolytic activity 
during hemodialysis rnigh! be caused by the removal of 
yet unidentifi ed low molecular weight factors. Such fac--
tors could stimulate the activation of proenzymes (e.g. 
plasma prokallikrein) or thc release oflysosomal protein-
ases into thc plasma of untreated patients. They rnigh! 
also be responsible for the stimulation of phagocytosis 
and/or increased protein breakdown within thc cells. 
Characterization of thc azocasein-splitting activity using 
more specific substrates might be a helpful tool in evalu-
ating thc origin and nature of Ihis proteolytic effecl. 
Summarizing our results, we could dearly demon-
strate that hemodialysis therapy is still connected with 
considerablc side effects probably duc to the contacl of 
white blood cells with the dialyzer cellophane mem-
branes. Improvement of such membranes leading 10 re-
duced liberation of proteolytic cell constitucnts should, 
thcrcfore, en hance the positive effects of hemodialysis 
thcrapy. 
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